5553 related articles for article (PubMed ID: 19232159)
1. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
2. Resistance to the phosphaturic and calcemic actions of parathyroid hormone during phosphate depletion. Prevention by 1,25-dihydroxyvitamin D3.
Gloor HJ; Bonjour JP; Caverzasio J; Fleisch H
J Clin Invest; 1979 Mar; 63(3):371-7. PubMed ID: 34630
[TBL] [Abstract][Full Text] [Related]
3. Interventions for metabolic bone disease in children with chronic kidney disease.
Hahn D; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the metabolism of 25-hydroxyvitamin D3 in primary cultures of chick kidney cells.
Trechsel U; Bonjour JP; Fleisch H
J Clin Invest; 1979 Jul; 64(1):206-17. PubMed ID: 109470
[TBL] [Abstract][Full Text] [Related]
5. The vitamin D receptor in osteoblastic cells but not secreted parathyroid hormone is crucial for soft tissue calcification induced by the proresorptive activity of 1,25(OH)
Nakamichi Y; Liu Z; Mori T; He Z; Yasuda H; Takahashi N; Udagawa N
J Steroid Biochem Mol Biol; 2023 Sep; 232():106351. PubMed ID: 37352941
[TBL] [Abstract][Full Text] [Related]
6. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.
Cozzolino M; Galassi A; Conte F; Mangano M; Di Lullo L; Bellasi A
Ther Clin Risk Manag; 2017; 13():679-689. PubMed ID: 28615947
[TBL] [Abstract][Full Text] [Related]
7. Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.
Khan BA; Qu X; Hua Y; Javaid MM
Cureus; 2023 Nov; 15(11):e48186. PubMed ID: 38050530
[TBL] [Abstract][Full Text] [Related]
8. Acute effects of propranolol and metoprolol on plasma concentrations of parathyroid hormone and calcitonin in uraemic patients.
Coevoet B; Desplan C; Sebert JL; Makdassi R; Gherbrand JD; Tolani M; Calmette C; Moukhtar MS; Fournier A
Proc Eur Dial Transplant Assoc; 1979; 16():649-55. PubMed ID: 44916
[TBL] [Abstract][Full Text] [Related]
9. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
Wesseling-Perry K; Salusky IB
Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
[TBL] [Abstract][Full Text] [Related]
10. Genomic mechanisms controlling renal vitamin D metabolism.
Meyer MB; Pike JW
J Steroid Biochem Mol Biol; 2023 Apr; 228():106252. PubMed ID: 36657729
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of bovine renal adenylate cyclase by urinary products.
Cloix JF; Cueille G; Funck-Brentano JL
Biomedicine; 1976 Jul; 25(6):215-8. PubMed ID: 9162
[TBL] [Abstract][Full Text] [Related]
12. The rationale for intermittent administration of PTH in the management of mineral and bone disorder of chronic kidney disease.
Pazianas M; Miller PD
J Nephrol; 2024 Mar; 37(2):337-342. PubMed ID: 37171706
[TBL] [Abstract][Full Text] [Related]
13. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol.
Christiansen C; Rødbro P; Christensen MS; Hartnack B; Transbøl I
Lancet; 1978 Sep; 2(8092 Pt 1):700-3. PubMed ID: 80633
[TBL] [Abstract][Full Text] [Related]
14. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
15. Diamine oxidase in renal failure.
Kopple JD; Tam CF; Wang M; Swendseid ME
Kidney Int Suppl; 1978 Jun; (8):S20-5. PubMed ID: 99597
[TBL] [Abstract][Full Text] [Related]
16. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD.
Wetmore JB; Santos PW; Mahnken JD; Krebill R; Menard R; Gutta H; Quarles LD
J Clin Endocrinol Metab; 2011 Jan; 96(1):E57-64. PubMed ID: 20943782
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system pH in uremia and the effects of hemodialysis.
Arieff AI; Guisado R; Massry SG; Lazarowitz VC
J Clin Invest; 1976 Aug; 58(2):306-11. PubMed ID: 8469
[TBL] [Abstract][Full Text] [Related]
18. Forestalling Hungry Bone Syndrome after Parathyroidectomy in Patients with Primary and Renal Hyperparathyroidism.
Carsote M; Nistor C
Diagnostics (Basel); 2023 Jun; 13(11):. PubMed ID: 37296804
[TBL] [Abstract][Full Text] [Related]
19. Chronotherapy of high-dose active vitamin D3 in haemodialysis patients with secondary hyperparathyroidsm: a repeated dosing study.
Tsuruoka S; Wakaumi M; Sugimoto K; Saito T; Fujimura A
Br J Clin Pharmacol; 2003 Jun; 55(6):531-7. PubMed ID: 12814446
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
